BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Key Stats

• Today's Range: $1.70 to $1.80
• 50-Day Range: $1.78 to $3.36
• 52-Week Range: $1.04 to $33.10
• Volume: 485,755 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $30.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 47% of companies evaluated by MarketBeat, and ranked 670th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BioVie has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioVie has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.58% of the outstanding shares of BioVie have been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 44.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.58% of the outstanding shares of BioVie have been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently decreased by 44.02%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.72

News Sentiment

BioVie has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioVie this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of BioVie is held by insiders.

Percentage Held by Institutions

Only 4.59% of the stock of BioVie is held by institutions.

BIVI Stock Analysis - Frequently Asked Questions

How have BIVI shares performed this year?

BioVie's stock was trading at $2.00 at the start of the year. Since then, BIVI shares have decreased by 13.5% and is now trading at $1.73.
View the best growth stocks for 2025 here.

Who are BioVie's major shareholders?

BioVie's top institutional investors include Drive Wealth Management LLC (0.34%) and Sanders Morris Harris LLC (0.23%). Insiders that own company stock include Steve Gorlin and Cuong V Do.
View institutional ownership trends.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI).

Company Calendar

• Today: 1/29/2025
• Next Earnings (Estimated): 2/11/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIVI
• CUSIP: N/A
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +74.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -182.62%
• Return on Assets: -102.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.95
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.54 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 17,770,000
• Free Float: 17,057,000
• Market Cap: $30.48 million
• Optionable: No Data
• Beta: 0.49